Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a significant milestone in the development of PC111, a first-in-class anti-Fas Ligand monoclonal antibody, following Dr. Roberta Lotti of Pincell Srl receiving the "Oscar of Italian Dermatology" from SIDeMaST. This accolade highlights the groundbreaking research published under the title "Blocking soluble Fas Ligand ameliorates pemphigus", which demonstrates PC111's efficacy in preventing blister formation by inhibiting keratinocyte apoptosis in pemphigus vulgaris, a severe autoimmune skin condition.
The recognition of Dr. Lotti's work not only validates the scientific community's interest in PC111 but also marks a pivotal moment for Scinai Immunotherapeutics as it advances PC111 as a lead asset. The company holds an option to acquire Pincell, further solidifying its commitment to developing innovative treatments for inflammation and immunology-related diseases. PC111's potential as a non-immunosuppressive, disease-modifying therapy offers hope for patients suffering from severe autoimmune skin conditions, representing a significant advancement in dermatological treatment options.
For more details on the research and the award, visit https://ibn.fm/51v14.
